Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Male Reproductive System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Reproductive System Neoplasm
Male Reproductive System Neoplasm

Subtype

Male Reproductive System Neoplasm

CI-CAN-00001107Explore in graph →

Non-malignant1,533 active trials27 approved drugs58 evidence items

NCIt: C3054

Overview
Statistics
Survival
Genomics29
Variants & evidence58
Drugs18
Trials6899
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (287)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 19, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 226–250 of 287 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Transrectal ultrasonographic parameters combined with total serum exosomes for the assessment of bone metastases in prostate cancer.
Lingxu Cui, Hua Hong, Guohua Wu et al. · Open Life Sci · Jan 1, 2026 · PMID 42699645 · candidate dictionary pubmed
Graph neural network-based risk stratification of prostate cancer using gene expression and SHAP interpretability.
Saeed Pirmoradi, Sevil Vaghefi Moghaddam, Mohammadreza Ardalan et al. · PLoS One · Jan 1, 2026 · PMID 42709904 · candidate dictionary pubmed
Urinary Trace Element Concentrations in Congolese Patients With Prostate Cancer: A Case-Control Study.
Pitchou Mukaz Mbey, Olivier Mukuku, Catherine Ugumba Saleh et al. · Prostate Cancer · Jan 1, 2026 · PMID 42707973 · candidate dictionary pubmed
Uncovering the diagnostic potential of seminal fluid beyond fertility: cfDNA methylation analysis for the detection of clinically significant prostate cancer.
Jennifer Geis, James F Smith, Tara Maddala et al. · PLoS One · Jan 1, 2026 · PMID 42715227 · candidate dictionary pubmed
Microsatellite instability in penile cancer: comparative analysis of primary tumors and metastases.
Hadson Silva Araujo, Gustavo Ramos Teixeira, Ana Carolina Laus et al. · Front Urol · Jan 1, 2026 · PMID 42718420 · candidate dictionary pubmed
Burden of Treatment-Induced Vasomotor Symptoms in Men With Prostate Cancer on Androgen-Deprivation Therapy: A Systematic Literature Review.
Mayank Ajmera, Kai-Jye Lou, Sydney Ng et al. · Prostate Cancer · Jan 1, 2026 · PMID 42724429 · candidate dictionary pubmed

Showing 226–250 of 287 publications

← Previous
1
…
9
10
11
12
Next →

Neutropenia in Patients With Castration-Resistant Prostate Cancer Treated Using Cabazitaxel and Prophylactic Administration of Pegfilgrastim.

Kazuhiko Oshinomi, Shota Kikuchi, Masahiro Kurokawa et al. · Adv Urol · Jan 1, 2026 · PMID 42732376 · candidate dictionary pubmed

Assessing the Level of Prostate Cancer Care in a Low-Resource Setting: Disease Pattern, Current Situation of Care, and the Need for Reform-A Retrospective Observational Study From East Oncology Centre, Sudan.

Mosab A A Alzubier, Eltahir Ahmed Eltahir, Hind Mohi Aldin Abd Allah et al. · Adv Urol · Jan 1, 2026 · PMID 42746128 · candidate dictionary pubmed

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

· N Engl J Med · 2020 · PMID 32343890 · validated civic_curation pubmed

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

· Br J Cancer · 2007 · PMID 17700571 · validated civic_curation pubmed

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

· N Engl J Med · 2015 · PMID 26510020 · validated civic_curation pubmed

Integrative clinical genomics of advanced prostate cancer.

· Cell · 2015 · PMID 26000489 · validated cbioportal_study pubmed

The association of Phosphatase and tensin homolog (PTEN) deletion and prostate cancer risk: A meta-analysis.

· Biomed Pharmacother · 2016 · PMID 27470558 · validated civic_curation pubmed

MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.

· Sci Rep · 2016 · PMID 27819322 · validated civic_curation pubmed

The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.

· Cancer Epidemiol Biomarkers Prev · 2015 · PMID 26108461 · validated civic_curation pubmed

Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.

· Oncotarget · 2016 · PMID 27626483 · validated civic_curation pubmed

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

· J Clin Oncol · 2019 · PMID 30865549 · validated civic_curation pubmed

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

· JAMA Oncol · 2016 · PMID 27262168 · validated civic_curation pubmed

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.

· JAMA Oncol · 2018 · PMID 29955787 · validated civic_curation pubmed

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

· Science · 2005 · PMID 16254181 · validated civic_curation pubmed

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

· N Engl J Med · 2014 · PMID 25184630 · validated civic_curation pubmed

Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.

· Int J Cancer · 2016 · PMID 26891277 · validated civic_curation pubmed

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

· Eur Urol · 2013 · PMID 23582881 · validated civic_curation pubmed

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

· J Clin Oncol · 2013 · PMID 23569316 · validated civic_curation pubmed

Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.

· Br J Cancer · 2013 · PMID 23329234 · validated civic_curation pubmed